Retrospective Cohort Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. May 29, 2020; 10(5): 117-128
Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.117
Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation
Kelley Núñez, Mohammad Hamed, Daniel Fort, David Bruce, Paul Thevenot, Ari Cohen
Kelley Núñez, Mohammad Hamed, Paul Thevenot, Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA 70121, United States
Daniel Fort, Center for Outcomes and Health Services Research, Research Administration, Ochsner Clinic Foundation, New Orleans, LA 70121, United States
David Bruce, Ari Cohen, Multi-Organ Transplant Program, Ochsner Clinic Foundation, New Orleans, LA 70121, United States
Author contributions: Thevenot P and Cohen A designed the research; Núñez K and Hamed M performed the research; Núñez K, Fort D, Bruce D, and Thevenot P analyzed the data; Núñez K wrote the manuscript; Hamed M, Thevenot P, and Cohen A revised the manuscript.
Institutional review board statement: This study was reviewed and approved by the Ochsner Institutional Review Board.
Informed consent statement: All patients in this study provided informed consent.
Conflict-of-interest statement: Authors have no conflict of interests to disclose.
Data sharing statement: No additional data are available for this study.
STROBE statement: Authors have read the STROBE Statement checklist of items and the manuscript was prepared and revised according to the STROBE Statement checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ari Cohen, MD, Professor, Surgeon, Multi-Organ Transplant, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, United States. acohen@ochsner.org
Received: December 31, 2019
Peer-review started: December 31, 2019
First decision: March 26, 2020
Revised: April 7, 2020
Accepted: May 5, 2020
Article in press: May 5, 2020
Published online: May 29, 2020
Processing time: 149 Days and 11 Hours
Core Tip

Core tip: As nonalcoholic fatty liver disease incidence continues to rise, steatosis, both micro- and macro- will continue to infiltrate the donor pool. While many transplant centers have success utilizing these extended criteria donor grafts, macrosteatotic grafts remain at increased risk. In this study, elevations in interleukin-33 and activated complement (C3a and C5a) in recipients immediately following reperfusion indicate that patients receiving macrosteatotic grafts may have more injury post-transplant. Through mRNA expression of donor biopsies, we identify potential target genes present in macrosteatotic grafts that could aid in deciphering which macrosteatotic grafts are safe for implantation.